Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation

Early-stage, lymph node-negative non-small cell lung cancer (NSCLC) is managed with surgical resection or stereotactic body radiation therapy (SBRT), which results in similar local control rates of approximately 90% [1 –6]. Despite effective eradication of the primary tumor, regional and distant recurrences remain and lead to progression-free survival (PFS) rates of only 60-80% two years post-treatment [3,5]. The role of adjuvant therapy following SBRT remains unclear, with considerations for treatment mostly ex trapolated from the surgical literature [7].

Source: Radiotherapy and Oncology - November 3, 2023 Category: Radiology Authors: Maria Thor, Kelly Fitzgerald, Aditya Apte, Jung Hun Oh, Aditi Iyer, Otasowie Odiase, Saad Nadeem, Ellen D. Yorke, Jamie Chaft, Abraham J. Wu, Michael Offin, Charles B Simone II, Isabel Preeshagul, Daphna Y. Gelblum, Daniel Gomez, Joseph O. Deasy, Andreas Tags: Original Article Source Type: research